Cellosaurus cell line CUTO-28 ROS1 p.G2032R (CVCL

Entry history
Cell line name	CUTO-28 ROS1 p.G2032R
Accession	CVCL_E6J7
Resource Identification Initiative	To cite this cell line use: CUTO-28 ROS1 p.G2032R (RRID:CVCL_E6J7)
Comments	Characteristics: The ROS1 mutation introduced is most prevalent among patients presenting relapsed disease. Shows resistance to ceritinib, crizotinib, entrectinib and lorlatinib (DOI=10.63028/10067/2105480151162165141). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations	Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (from parent cell line). Mutation; HGNC; HGNC:10261; ROS1; Simple_edited; p.Gly2032Arg (c.6094G>A) (p.Gly2026Arg, c.6076G>A); ClinVar=VCV000376139; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (DOI=10.63028/10067/2105480151162165141).
Disease	Lung adenocarcinoma (NCIt: C3512)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_C8T2 (CUTO-28)
Category	Cancer cell line
Publications	DOI=10.63028/10067/2105480151162165141 Terrones M. Profiling targeted therapy responses in ROS1+ non-small cell lung cancer using genomically engineered patient-derived cell lines. Thesis PhD (2024); University of Antwerp; Antwerp; Belgium
Entry creation	10-Apr-2025
Last entry update	10-Apr-2025
Version number	1